Lila Feisee

Array ( [id] => 2842127 [patent_doc_number] => 05106618 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 1992-04-21 [patent_title] => 'Method of treating protozoal gastrointestinal disorders by administering hyperimmune milk product' [patent_app_type] => 1 [patent_app_number] => 7/355786 [patent_app_country] => US [patent_app_date] => 1989-05-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4516 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 227 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/05/106/05106618.pdf [firstpage_image] =>[orig_patent_app_number] => 355786 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 2672056 [patent_doc_number] => 05073540 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 1991-12-17 [patent_title] => 'Composite binding site drugs' [patent_app_type] => 1 [patent_app_number] => 7/351764 [patent_app_country] => US [patent_app_date] => 1989-05-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7945 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 125 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/05/073/05073540.pdf [firstpage_image] =>[orig_patent_app_number] => 351764 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 3784807 [patent_doc_number] => 05821340 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 1998-10-13 [patent_title] => 'Inducible endothelial surface protein mediating lymphoid and tumor cell adhesion: antibodies and uses' [patent_app_type] => 1 [patent_app_number] => 7/310201 [patent_app_country] => US [patent_app_date] => 1989-02-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 5 [patent_no_of_words] => 10526 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/05/821/05821340.pdf [firstpage_image] =>[orig_patent_app_number] => 310201 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 2970820 [patent_doc_number] => 05194384 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 1993-03-16 [patent_title] => 'Method for preparing human meloma vaccine' [patent_app_type] => 1 [patent_app_number] => 7/298992 [patent_app_country] => US [patent_app_date] => 1989-01-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6693 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 145 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/05/194/05194384.pdf [firstpage_image] =>[orig_patent_app_number] => 298992 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 3622425 [patent_doc_number] => 05614610 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 1997-03-25 [patent_title] => 'Tumor immunotherapy using anti-idiotypic antibodies' [patent_app_type] => 1 [patent_app_number] => 7/225446 [patent_app_country] => US [patent_app_date] => 1988-07-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 55 [patent_no_of_words] => 36556 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 36 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/05/614/05614610.pdf [firstpage_image] =>[orig_patent_app_number] => 225446 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 2809298 [patent_doc_number] => 05078998 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 1992-01-07 [patent_title] => 'Hybrid ligand directed to activation of cytotoxic effector T lymphocytes and target associated antigen' [patent_app_type] => 1 [patent_app_number] => 6/762048 [patent_app_country] => US [patent_app_date] => 1985-08-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 10 [patent_no_of_words] => 15534 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 41 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/05/078/05078998.pdf [firstpage_image] =>[orig_patent_app_number] => 762048 [rel_patent_id] =>[rel_patent_doc_number] =>)